These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 24614127)

  • 21. Efficacy of the pentavalent rotavirus vaccine, RotaTeq® (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen).
    Dennehy PH; Vesikari T; Matson DO; Itzler RF; Dallas MJ; Goveia MG; DiNubile MJ; Heaton PM; Ciarlet M
    Hum Vaccin; 2011 May; 7(5):563-8. PubMed ID: 21441783
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Breastfeeding linked to the reduction of both rotavirus shedding and IgA levels after Rotarix® immunization in Mexican infants.
    Bautista-Marquez A; Velasquez DE; Esparza-Aguilar M; Luna-Cruz M; Ruiz-Moran T; Sugata K; Jiang B; Parashar U; Patel M; Richardson V
    Vaccine; 2016 Oct; 34(44):5284-5289. PubMed ID: 27663670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of pentavalent rotavirus vaccine in Japan: a randomized, double-blind, placebo-controlled, multicenter trial.
    Iwata S; Nakata S; Ukae S; Koizumi Y; Morita Y; Kuroki H; Tanaka Y; Shizuya T; Schödel F; Brown ML; Lawrence J
    Hum Vaccin Immunother; 2013 Aug; 9(8):1626-33. PubMed ID: 23732903
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of the oral pentavalent rotavirus vaccine in Mali.
    Sow SO; Tapia M; Haidara FC; Ciarlet M; Diallo F; Kodio M; Doumbia M; Dembélé RD; Traoré O; Onwuchekwa UU; Lewis KD; Victor JC; Steele AD; Neuzil KM; Kotloff KL; Levine MM
    Vaccine; 2012 Apr; 30 Suppl 1():A71-8. PubMed ID: 22520140
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5).
    Itzler R; Koch G; Matson DO; Gothefors L; Van Damme P; Dinubile MJ; Heaton PM
    BMC Pediatr; 2010 Jun; 10():42. PubMed ID: 20540778
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Cortese MM; Parashar UD;
    MMWR Recomm Rep; 2009 Feb; 58(RR-2):1-25. PubMed ID: 19194371
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I trial of RV3-BB rotavirus vaccine: a human neonatal rotavirus vaccine.
    Danchin M; Kirkwood CD; Lee KJ; Bishop RF; Watts E; Justice FA; Clifford V; Cowley D; Buttery JP; Bines JE
    Vaccine; 2013 May; 31(23):2610-6. PubMed ID: 23597719
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Phase III open-label, randomized, active controlled clinical study to assess safety, immunogenicity and lot-to-lot consistency of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants.
    Rathi N; Desai S; Kawade A; Venkatramanan P; Kundu R; Lalwani SK; Dubey AP; Venkateswara Rao J; Narayanappa D; Ghildiyal R; Gogtay N; Venugopal P; Palkar S; Munshi R; Kang G; Babji S; Bavdekar A; Juvekar S; Ganguly N; Niyogi P; Ghosh Uttam K; Rajani HS; Kondekar A; Kumbhar D; Mohanlal S; Agarwal MC; Shetty P; Antony K; Gunale B; Dharmadhikari A; Tang Y; Kulkarni PS; Flores J
    Vaccine; 2018 Dec; 36(52):7943-7949. PubMed ID: 30420116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of an incomplete RotaTeq (RV5) vaccination regimen in preventing rotavirus gastroenteritis in the United States.
    Wang FT; Mast TC; Glass RJ; Loughlin J; Seeger JD
    Pediatr Infect Dis J; 2013 Mar; 32(3):278-83. PubMed ID: 23014356
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants.
    Phua KB; Quak SH; Lee BW; Emmanuel SC; Goh P; Han HH; De Vos B; Bock HL
    J Infect Dis; 2005 Sep; 192 Suppl 1():S6-S16. PubMed ID: 16088807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and immunogenicity of live-attenuated human rotavirus vaccine in breast-fed and formula-fed European infants.
    Vesikari T; Prymula R; Schuster V; Tejedor JC; Cohen R; Bouckenooghe A; Damaso S; Han HH
    Pediatr Infect Dis J; 2012 May; 31(5):509-13. PubMed ID: 22228235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pentavalent rotavirus vaccine (RotaTeq): a review of its use in the prevention of rotavirus gastroenteritis in Europe.
    Plosker GL
    Drugs; 2010 Jun; 70(9):1165-88. PubMed ID: 20518582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention of rotavirus disease: guidelines for use of rotavirus vaccine.
    American Academy of Pediatrics Committee on Infectious Diseases
    Pediatrics; 2007 Jan; 119(1):171-82. PubMed ID: 17200286
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-World Effectiveness of Pentavalent Rotavirus Vaccine Among Bedouin and Jewish Children in Southern Israel.
    Leshem E; Givon-Lavi N; Tate JE; Greenberg D; Parashar UD; Dagan R
    Clin Infect Dis; 2016 May; 62 Suppl 2():S155-60. PubMed ID: 27059350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 oral suspension (liquid formulation) in Finnish infants.
    Vesikari T; Karvonen A; Bouckenooghe A; Suryakiran PV; Smolenov I; Han HH
    Vaccine; 2011 Mar; 29(11):2079-84. PubMed ID: 21238572
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk of intussusception following administration of a pentavalent rotavirus vaccine in US infants.
    Shui IM; Baggs J; Patel M; Parashar UD; Rett M; Belongia EA; Hambidge SJ; Glanz JM; Klein NP; Weintraub E
    JAMA; 2012 Feb; 307(6):598-604. PubMed ID: 22318281
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and immunogenicity of RV3-BB human neonatal rotavirus vaccine administered at birth or in infancy: a randomised, double-blind, placebo-controlled trial.
    Bines JE; Danchin M; Jackson P; Handley A; Watts E; Lee KJ; West A; Cowley D; Chen MY; Barnes GL; Justice F; Buttery JP; Carlin JB; Bishop RF; Taylor B; Kirkwood CD;
    Lancet Infect Dis; 2015 Dec; 15(12):1389-97. PubMed ID: 26318715
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Methodology and lessons-learned from the efficacy clinical trial of the pentavalent rotavirus vaccine in Bangladesh.
    Zaman K; Yunus M; El Arifeen S; Azim T; Faruque AS; Huq E; Hossain I; Luby SP; Victor JC; Dallas MJ; Lewis KD; Rivers SB; Steele AD; Neuzil KM; Ciarlet M; Sack DA
    Vaccine; 2012 Apr; 30 Suppl 1():A94-100. PubMed ID: 22520143
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concomitant use of the oral pentavalent human-bovine reassortant rotavirus vaccine and oral poliovirus vaccine.
    Ciarlet M; Sani-Grosso R; Yuan G; Liu GF; Heaton PM; Gottesdiener KM; Arredondo JL; Schödel F
    Pediatr Infect Dis J; 2008 Oct; 27(10):874-80. PubMed ID: 18756184
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity of the pentavalent rotavirus vaccine in African infants.
    Armah GE; Breiman RF; Tapia MD; Dallas MJ; Neuzil KM; Binka FN; Sow SO; Ojwando J; Ciarlet M; Steele AD
    Vaccine; 2012 Apr; 30 Suppl 1():A86-93. PubMed ID: 22520142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.